Physician profile
John Michael Li
NPI 1972769750
$7,651.90
in general payments reported to CMS, 2019-2025
37 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $144 · 2021: $497 · 2022: $855 · 2023: $1,325 · 2024: $1,965 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,302 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.92 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,345.84 | 2021-2025 | |
| Ucb, INC. | $506.92 | 2019-2025 | Zilbrysq |
| Argenx US, INC. | $432.52 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $422.43 | 2019-2025 | Ultomiris |
| Csl Behring | $369.79 | 2019-2025 | Hizentra, Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $368.17 | 2023-2025 | Hyqvia, Gammagard |
| Grifols USA, LLC | $356.65 | 2023-2025 | Gamunex-C |
| Alnylam Pharmaceuticals INC. | $269.69 | 2022-2025 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $229.95 | 2023-2025 | Austedo Xr, Ajovy, Austedo |
| Avanir Pharmaceuticals, INC. | $220.83 | 2019 | |
| Lundbeck LLC | $216.08 | 2019-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $201.91 | 2022 | |
| Tanabe Pharma America, INC. | $190.63 | 2019-2025 | Radicava |
| Amgen INC. | $189.14 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $166.38 | 2019-2025 | Kisunla, Emgality, Reyvow |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $157.03 | 2021 | |
| Adamas Pharmaceuticals, INC. | $129.53 | 2019 | |
| Neurocrine Biosciences, INC. | $106.38 | 2019-2023 | Ingrezza |
| Catalyst Pharmaceuticals, INC. | $82.69 | 2022-2023 | Firdapse |
| Pfizer INC. | $81.38 | 2023-2025 | |
| Sk Life Science, INC. | $80.72 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $77.44 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $76.19 | 2023-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $74.66 | 2024-2025 | |
| Horizon Therapeutics Plc | $44.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $42.62 | 2019 | |
| Neurelis, INC. | $33.92 | 2022-2024 | Valtoco |
| Octapharma USA, INC. | $27.71 | 2022 | |
| Assertio Therapeutics, INC. | $23.09 | 2020 | |
| Merz North America, INC. | $22.56 | 2019 | |
| Averitas Pharma INC. | $17.98 | 2024 | Qutenza |
| Eisai INC. | $15.41 | 2024 | |
| Vertical Pharmaceuticals, LLC | $15.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.17 | 2024 | Nuedexta |
| Edw Pharma, INC. | $14.97 | 2019 | |
| Kyowa Kirin, INC. | $13.81 | 2019 | |
| Almatica Pharma LLC | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Michael Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.